<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31384">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02698137</url>
  </required_header>
  <id_info>
    <org_study_id>QUASIE2</org_study_id>
    <nct_id>NCT02698137</nct_id>
  </id_info>
  <brief_title>Quality Assessment in Endoscopic Retrograde Cholangiopancreatography(ERCP)</brief_title>
  <acronym>QUASIE2</acronym>
  <official_title>Quality Assessment in ERCP: Risk Factors for Procedure-related Complications in Patients Undergoing ERCP in the Setting of an Endoscopy Training Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Hospital Colentina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Hospital Colentina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will prospectively collect patient and procedure-related data in an
      observational study in order to detect patient and procedure-related risk factors for poor
      outcome (i.e. technical failure of the procedure; procedure-related complications).

      Data will be prospectively reported using standard report forms and patients will be
      followed up to 30 days to detect late-onset complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>procedure-related adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>the percentage of patients experiencing procedure-related adverse events (i.e post-ERCP pancreatitis; postERCP cholangitis; perforation; postERCP bleeding or death) occuring within 30 days of the procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>technical failure of the procedure</measure>
    <time_frame>30 days</time_frame>
    <description>percentage of procedures where the operator was unable to achieve the desired therapeutic goal (i.e selective cannulation, stone removal, stenting)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Cholangiopancreatography, Endoscopic Retrograde</condition>
  <condition>Common Bile Duct Lithiasis</condition>
  <condition>Biliary Strictures</condition>
  <condition>Bile Duct and Pancreatic Tumors</condition>
  <eligibility>
    <study_pop>
      <textblock>
        all consecutive patients undergoing ERCP in an endoscopy training program setting
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients undergoing ERCP with attempted cannulation of either the major or minor
             papilla

        Exclusion Criteria:

          -  refusal to sign the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodor Voiosu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Hospital Colentina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theodor Voiosu, MD, PhD</last_name>
    <phone>0040213180604</phone>
    <email>theodor.voiosu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreea Bengus, MD, PhD</last_name>
    <phone>0040213180604</phone>
    <email>andreeabengus@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GI Endoscopy Unit, Department of Gastroenterology and Hepatology, University Hospital Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agata Ladic, MD, PhD</last_name>
      <phone>+385-1-2388041</phone>
    </contact>
    <investigator>
      <last_name>Agata Ladic, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Department, Colentina Hospital</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodor Voiosu, PhD, MD</last_name>
      <phone>0040213173245</phone>
      <phone_ext>5117</phone_ext>
    </contact>
    <investigator>
      <last_name>Theodor Voiosu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Romania</country>
  </location_countries>
  <reference>
    <citation>Voiosu TA, Bengus A, Haidar A, Rimbas M, Zlate A, Balanescu P, Voiosu A, Voiosu R, Mateescu B. Antibiotic Prophylaxis Prior to Elective ERCP Does Not Alter Cholangitis Rates or Shorten Hospital Stay: Results of an Observational Prospective Study of 138 Consecutive ERCPS. Maedica (Buchar). 2014 Dec;9(4):328-32.</citation>
    <PMID>25705300</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 24, 2016</lastchanged_date>
  <firstreceived_date>February 24, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Hospital Colentina</investigator_affiliation>
    <investigator_full_name>dr. Theodor Alexandru Voiosu</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Lithiasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
